Literature DB >> 11401524

Expression of IL-17 mRNA in ovarian cancer.

T Kato1, H Furumoto, T Ogura, Y Onishi, M Irahara, S Yamano, M Kamada, T Aono.   

Abstract

IL-17 is considered as a proinflammatory cytokine. We have demonstrated IL-17 is an angiogenic factor and promotes tumor growth in murine tumor models. In this report, we investigated the expression of IL-17 mRNA by RT-PCR and the relationship between IL-17 expression and microvascular density in ovarian cancer. IL-17 mRNA was expressed in 11 (64.7%) of 17 ovarian cancer. And the average number of blood vessels observed in IL-17 positive tumors (173.4 +/- 55.1/mm(2)) was significantly higher than that in negative tumors (107.7 +/- 57.8/mm(2)). These results indicated IL-17 is expressed in a considerable proportion of ovarian cancer and promotes tumor angiogenesis. There was no significant relationship between IL-17 expression and clinicopathologic parameters. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401524     DOI: 10.1006/bbrc.2001.4618

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  50 in total

1.  Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.

Authors:  Qi Huang; Jinshuo Fan; Xin Qian; Zhilei Lv; Xiuxiu Zhang; Jieli Han; Feng Wu; Caiyun Chen; Jiao Du; Mengfei Guo; Guorong Hu; Yang Jin
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-30       Impact factor: 4.553

2.  Cytokine comparisons between women with breast cancer and women with a negative breast biopsy.

Authors:  Debra E Lyon; Nancy L McCain; Jeanne Walter; Christine Schubert
Journal:  Nurs Res       Date:  2008 Jan-Feb       Impact factor: 2.381

3.  A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer.

Authors:  S Reppert; I Boross; M Koslowski; Ö Türeci; S Koch; H A Lehr; S Finotto
Journal:  Nat Commun       Date:  2011-12-20       Impact factor: 14.919

Review 4.  The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review.

Authors:  Simone Punt; Jessica M Langenhoff; H Putter; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

5.  Prognostic significance of interleukin-17 in solid tumors: a meta-analysis.

Authors:  Yunhui Zeng; Qiongwen Zhang; Hong Wang; Minxun Lu; Hongyu Kong; Yingyi Zhang; Huashan Shi
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 6.  IL-17RC: a partner in IL-17 signaling and beyond.

Authors:  Allen W Ho; Sarah L Gaffen
Journal:  Semin Immunopathol       Date:  2009-12-13       Impact factor: 9.623

7.  Increased expression of IL17A in human gastric cancer and its potential roles in gastric carcinogenesis.

Authors:  Xiaoqin Wu; Zhirong Zeng; Lixia Xu; Jun Yu; Qinghua Cao; Minhu Chen; Joseph J Y Sung; Pinjin Hu
Journal:  Tumour Biol       Date:  2014-02-26

8.  Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.

Authors:  T Xiang; H Long; L He; X Han; K Lin; Z Liang; W Zhuo; R Xie; B Zhu
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

Review 9.  Th17 cells in human disease.

Authors:  Laura A Tesmer; Steven K Lundy; Sujata Sarkar; David A Fox
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.